M Lynn Savoie
Overview
Explore the profile of M Lynn Savoie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, et al.
Leukemia
. 2023 Nov;
38(1):58-66.
PMID: 37935977
Prior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a...
2.
Khadadah F, Cerquozzi S, Olney H, Fraga C, Dudebout J, Xenocostas A, et al.
Leuk Res
. 2023 Sep;
133:107374.
PMID: 37657146
Background: Asciminib is a novel drug specifically targeting ABL myristoyl pocket in the ABL1 protein. Methods: Forty one patients with chronic myeloid leukemia treated with asciminib from 2018 to 2022...
3.
Pagel J, Othus M, Garcia-Manero G, Fang M, Radich J, Rizzieri D, et al.
JCO Oncol Pract
. 2020 Feb;
16(6):e464-e475.
PMID: 32048933
Purpose: Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone....
4.
Kalra A, Williamson T, Daly A, Savoie M, Stewart D, Khan F, et al.
Biol Blood Marrow Transplant
. 2016 Jun;
22(9):1654-1663.
PMID: 27246372
Although previous studies involving allogeneic hematopoietic cell transplantation (HCT) without in vivo T cell depletion by rabbit antithymocyte globulin (ATG) have reported a substantial survival difference between D-R- and D+R-...
5.
Anderson K, Chambers C, Lam N, Yau P, Cusano F, Savoie M, et al.
J Oncol Pharm Pract
. 2014 Feb;
21(1):19-25.
PMID: 24503243
Background: Oral tyrosine kinase inhibitors are the standard of care for chronic myeloid leukemia. Tyrosine kinase inhibitors are administered in an outpatient setting for an indefinite period which may negatively...
6.
Armand P, Kim H, Zhang M, Perez W, Dal Cin P, Klumpp T, et al.
Biol Blood Marrow Transplant
. 2011 Aug;
18(2):280-8.
PMID: 21810400
Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal...
7.
Geddes M, Kangarloo S, Naveed F, Quinlan D, Chaudhry M, Stewart D, et al.
Biol Blood Marrow Transplant
. 2008 Jan;
14(2):220-8.
PMID: 18215782
Low plasma busulfan (Bu) area under the concentration-time curve (AUC) is associated with graft failure and relapsed leukemias, and high AUC with toxicities when Bu is used orally or i.v....
8.
Makowsky M, Warkentin D, Savoie M
Ann Pharmacother
. 2005 Jun;
39(7-8):1365-6.
PMID: 15956243
No abstract available.